RPD heads into the post-earnings stretch in a paradox: a Q1 beat that sent the stock up 15% on the week, paired with a wave of analyst target cuts that are keeping the ceiling firmly in view.
The numbers tell a credible recovery story. The cybersecurity software company printed Q1 earnings and revenues above consensus, issued Q2 ARR guidance of approximately $820M, and projected FY2026 non-GAAP operating income of $112M-$118M. The stock responded — closing at $6.68 after a 15% weekly surge and a 24% gain over the past month. That recovery is real. It is also coming off a very low base, with the stock still down 57% year-to-date after a catastrophic Q4 2025 report that sent shares down 32% in a single day.
The positioning picture is decidedly mixed. Short interest has climbed sharply — up 8.3% in a week to 10.7% of free float, the highest level in the 30-day window, reflecting bears adding aggressively ahead of and through the print. What makes the setup unusual is that this increase in short positioning has not been met with tighter borrow conditions. Cost to borrow is a benign 0.44% — down 38% over the past month — and availability remains loose. That combination of elevated short interest and cheap, plentiful borrow suggests shorts are not being squeezed; they are positioned comfortably and adding at will. The ORTEX short score nudged to 53.6 on May 5, a noticeable step up from the mid-48 range seen through most of April, driven by the acceleration in estimated short shares over the final week of the period. Options positioning sits mildly above its recent average — the put/call ratio at 0.74 against a 20-day mean of 0.70 — but is far from elevated, nowhere near the 0.85 levels seen in late April when hedging demand was at its peak.
The Street's initial read on the earnings beat has been to cut targets, not to upgrade. Stifel and Scotiabank both lowered their price objectives to $7 on May 6, while Piper Sandler moved to $8 from $10. The direction has been consistent since February: JPMorgan cut to $11 from $20 in the immediate aftermath of the Q4 collapse, Barclays took its target to $8 from $15, and William Blair downgraded the stock to Market Perform in late April. The mean analyst target now sits at $7.56 — a modest 13% above the current price — which is a thin cushion for a name that just printed a 32% single-day decline six months ago. The bull case rests on AI-integration driving platform adoption and improving operating margins; the bear case centres on soft Risk and Exposure Management demand, leadership transition risk, and near-term profitability pressure from the AI pivot. The EV/EBITDA at 6.7x is undemanding, but the forward EPS momentum score at the 10th percentile of the universe signals the earnings revision cycle has not yet turned supportive.
One data thread worth monitoring is the divergence in short interest timing. From March through early April, RPD carried roughly 6.4M shares short — a steady baseline. Between April 10 and April 22, that figure dropped sharply to around 5.2M, coinciding with a period when cost-to-borrow was running above 0.5%. From April 23 onwards, it ratcheted back up to nearly 7.0M — just as borrow costs fell back to 0.43-0.48%. That pattern — shorts retreating when borrow gets expensive, returning when it cheapens — suggests an opportunistic rather than convicted short base, which could matter if the next catalyst forces a rapid cover.
Atlantis comparisons between the correlated peer universe add some context. TEAM surged 32% on the week — the standout mover — while HUBS and MNDY added 9% and 13% respectively. RPD's 15% gain is strong in absolute terms but sits in the middle of the pack for a post-earnings reaction in a rising software tape. Whether that gap to TEAM — which also reported strong results — reflects a valuation discount warranted by RPD's ongoing restructuring, or an opportunity, is the central debate heading into the next quarter's data point.
The next marker is the earnings call transcript detail and whether management can give more specificity on the ARR trajectory — the $820M Q2 target is the number to watch, as it will determine whether the shorts rebuilding at 10.7% of float are prescient or premature.
See the live data behind this article on ORTEX.
Open RPD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
